An Open Label, Randomized, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 in Pediatric Subjects Aged 10 to Less than 18 Years for the Treatment of Relapsing Remitting Multiple Sclerosis, with Optional Open-Label Extension (105MS306)
Active, not recruitingCTIS2023-505624-56-00
Biogen Idec Research LimitedRelapsing Remitting Multiple Sclerosis (RRMS)
Start: 2019-08-07Target: 29Updated: 2025-09-11